We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.02% | 45.67 | 13,416 | 11:25:26 |
From May 2019 to May 2024
By Dominic Chopping
STOCKHOLM--Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of leukemia drug Arzerra (ofatumumab) during the third quarter of 2014 were GBP13.8 million.
This figure consists of net sales in the US of GBP5.3 million and in the rest of the world of GBP8.5 million.
Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK27 million.
The rest of world sales for the third quarter were enhanced by sales related to the supply of ofatumumab for clinical trials run by other companies.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
